scholarly journals Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease

2018 ◽  
Vol 13 (4) ◽  
pp. 337-339
Author(s):  
Dimitrios Patoulias ◽  
Maria Kalogirou
Sign in / Sign up

Export Citation Format

Share Document